Mednet Logo

With the recent approval of quizartinib, what is your preferred first-line FLT3 inhibitor in combination with chemotherapy for a fit AML patient with a FLT3-ITD mutation?

Community PollStarted

Which FLT3 inhibitor would you use first-line in combination with chemotherapy for a fit FLT3-ITD mutated AML patient?

6 physicians have voted

Join Mednetto vote and see how they answered.